+1 518-300-1218
Life Science

Animal Vaccines Market Size, Growth & Outlook

Animal Vaccines Market Size, Growth & Outlook
REPORT ID: FMI-0337 || VIEW: 64

Animal Vaccines Market by Product Type (Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vaccines, and DNA Vaccines) and Animal Type (Companion animals, Cattle, Fish, Pigs, Poultry, and Sheep]: Global Opportunity Analysis and Industry Forecast, 2021 - 2028

  • Report description
  • Table of Content

Veterinary vaccines are used for prevention of diseases that affect animals. Animal vaccination is a cost-effective solution to maintain animal health and sustainability, offering various benefits such as improved animal health & welfare of companion animals, improvement in livestock products, and prevention of transmission of diseases from animal to humans. Humans are largely dependent on animals, as they are the major source of milk, meat, and other dairy products. Thus, the demand for animal products also increases with rise in population, fueling the production of vaccines for attle, pigs, poultry, and sheep. 

 

The animal vaccines market is segmented on the basis of product type, animal type, and geography. By product type, the market is categorized into attenuated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, conjugate vaccines, recombinant vaccines, and DNA vaccines. Based on animal type, it is classified into companion animals, cattle, pigs, poultry, and sheep. The companion animals segment is subsegmented into dogs, cats, and others. Based on region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

 

The animal vaccines market is growing at a steady pace due to increase in pet ownership in developed countries and rise in number of cattle & poultry in developing countries. Furthermore, rise in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the market growth. Moreover, rise in demand for animal vaccines has led to the emergence of multiple new vaccines However, lack of animal health awareness and possibility of adverse impact on veterinary vaccines on human and other animal health can restrain the growth for animal vaccines market. Furthermore, the advanced in vaccine products and production of animal vaccines for hybrid animals can help open new avenues for the growth of the animal vaccines market.

 

KEY BENEFITS
• The global animal vaccines market report provides an extensive analysis of the current market trends and future estimations prevailing in the market.
• The market estimations from 2021 to 2028 are based on high-end analysis of the key developments.
• The market scenario is comprehensively analyzed with respect to the product type and animal type.
• Recent developments and key manufacturers are listed and analyzed to understand the competitive market scenario.
• In-depth geographical analysis helps understand the regional market, which assists in strategic business planning.

 

KEY MARKET SEGMENTS

• By Product
o Attenuated Vaccines
o Inactivated Vaccines
o Subunit Vaccines
o Toxoid Vaccines
o Conjugate Vaccines
o Recombinant Vaccines
o DNA Vaccines

 

• By Animal Type
o Companion Animals
 Dogs
 Cats
 Others
o Cattle
o Fish
o Pigs
o Poultry
o Sheep

 

• By Region
o North America
 U.S.
 Canada
 Mexico
o Europe
 Germany
 UK
 France
 Italy
 Rest of Europe
o Asia-Pacific
 Japan
 China
 Australia
 India
 South Korea
 Taiwan
 Rest of Asia-Pacific
o LAMEA
 Brazil
 Turkey
 Venezuela
 Saudi Arabia
 Rest of LAMEA

 

The key players profiled in this report include the following:
• Bayer AG
• Eli Lilly and Company
• Boehringer
• Ingelheim GmbH
• Merck & Co., Inc.
• Zoetis Inc.
• Ceva Santé Animale
• Sanofi S.A.
• Nutreco N.V.
• Virbac S.A.

Chapter: 1: INTRODUCTION

1.1. Report Description
1.2. Key Benefits
1.3. Key Market Segments
1.4. Research Methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top winning strategies
3.2.2. Top investment pockets

3.3. Government Regulations

3.3.1. Center for Veterinary Biologics (CVB)

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Growth in demand for pet insurance
3.4.1.2. Increase in prevalence of animal diseases
3.4.1.3. Growth in ownership of companion animal
3.4.1.4. Rise in animal health expenditure

3.4.2. Restraints

3.4.2.1. Highly competitive meat and milk prices
3.4.2.2. Adverse impact of veterinary vaccines on human and animal health

3.4.3. Opportunities

3.4.3.1. Advancement in vaccine products
3.4.3.2. Increase in demand for hybrid animals

Chapter: 4: ANIMAL VACCINES MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Attenuated Vaccines

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Market analysis, by country

4.3. Inactivated Vaccines

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Market analysis, by country

4.4. Subunit Vaccines

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Market analysis, by country

4.5. Toxoid Vaccines

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Market analysis, by country

4.6. Conjugate Vaccines

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast
4.6.4. Market analysis, by country

4.7. Recombinant Vaccines

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast
4.7.4. Market analysis, by country

4.8. DNA Vaccines

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast
4.8.4. Market analysis, by country

Chapter: 5: ANIMAL VACCINES MARKET, BY ANIMAL TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Companion animal

5.2.1. Market size and forecast, by type

5.2.1.1. Dogs
5.2.1.2. Cats
5.2.1.3. Other Companion animal vaccines segment

5.2.2. Market size and forecast, by region
5.2.3. Market analysis, by country

5.3. Cattle

5.3.1. Market size and forecast
5.3.2. Market analysis, by country

5.4. Pigs

5.4.1. Market size and forecast
5.4.2. Market analysis, by country

5.5. Poultry

5.5.1. Market size and forecast
5.5.2. Market analysis, by country

5.6. Sheep

5.6.1. Market size and forecast
5.6.2. Market analysis, by country

Chapter: 6: ANIMAL VACCINES MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast, by product
6.2.4. Market size and forecast, by animal
6.2.5. Market size and forecast, by country

6.2.5.1. U.S. market size and forecast, by product
6.2.5.2. U.S. market size and forecast, by animal
6.2.5.3. Canada market size and forecast, by product
6.2.5.4. Canada market size and forecast, by animal
6.2.5.5. Mexico market size and forecast, by product
6.2.5.6. Mexico market size and forecast, by animal

6.3. Europe

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast, by product
6.3.4. Market size and forecast, by animal
6.3.5. Market size and forecast, by country

6.3.5.1. Germany market size and forecast, by product
6.3.5.2. Germany market size and forecast, by animal
6.3.5.3. France market size and forecast, by product
6.3.5.4. France market size and forecast, by animal
6.3.5.5. UK market size and forecast, by product
6.3.5.6. UK market size and forecast, by animal
6.3.5.7. Italy market size and forecast, by product
6.3.5.8. Italy market size and forecast, by animal
6.3.5.9. Rest of Europe market size and forecast, by product
6.3.5.10. Rest of Europe market size and forecast, by animal

6.4. Asia-Pacific

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast, by product
6.4.4. Market size and forecast, by animal
6.4.5. Market size and forecast, by country

6.4.5.1. Japan market size and forecast, by product
6.4.5.2. Japan market size and forecast, by animal
6.4.5.3. China market size and forecast, by product
6.4.5.4. China market size and forecast, by animal
6.4.5.5. Australia market size and forecast, by product
6.4.5.6. Australia market size and forecast, by animal
6.4.5.7. India market size and forecast, by product
6.4.5.8. India market size and forecast, by animal
6.4.5.9. South Korea market size and forecast, by product
6.4.5.10. South Korea market size and forecast, by animal
6.4.5.11. Rest of Asia-Pacific market size and forecast, by product
6.4.5.12. Rest of Asia-Pacific market size and forecast, by animal

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast, by product
6.5.4. Market size and forecast, by animal
6.5.5. Market size and forecast, by country

6.5.5.1. Brazil market size and forecast, by product
6.5.5.2. Brazil market size and forecast, by animal
6.5.5.3. Saudi Arabia market size and forecast, by product
6.5.5.4. Saudi Arabia market size and forecast, by animal
6.5.5.5. Rest of LAMEA market size and forecast, by product
6.5.5.6. Rest of LAMEA market size and forecast, by animal

Chapter: 7: COMPANY PROFILES

7.1. Anicon Labor GmbH

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio

7.2. Boehringer Ingelheim GmbH

7.2.1. Company overview
7.2.2. Operating business segments
7.2.3. Business performance

7.3. Ceva Sant Animale

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves & developments, 2014-2016

7.4. Hygieia Biological Laboratories

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio

7.5. Merck & company Inc.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. Romvac company S.A.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio

7.7. Sanofi S.A.

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. Vaxxinova Gmbh-Germany

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments

7.9. Virbac S.A

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. Zoetis Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves & developments

Still have a doubt?

Enquire Before Buying

Select Licence Type

Avail customized purchase options

Request Customization